IN2014DN08862A - - Google Patents

Info

Publication number
IN2014DN08862A
IN2014DN08862A IN8862DEN2014A IN2014DN08862A IN 2014DN08862 A IN2014DN08862 A IN 2014DN08862A IN 8862DEN2014 A IN8862DEN2014 A IN 8862DEN2014A IN 2014DN08862 A IN2014DN08862 A IN 2014DN08862A
Authority
IN
India
Prior art keywords
cells
stem cells
immortalized stem
tissues
immortalized
Prior art date
Application number
Inventor
Minoru Ueda
Original Assignee
Quarrymen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quarrymen Corp filed Critical Quarrymen Corp
Publication of IN2014DN08862A publication Critical patent/IN2014DN08862A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0664—Dental pulp stem cells, Dental follicle stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • C12N5/0672—Stem cells; Progenitor cells; Precursor cells; Oval cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/602—Sox-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/604—Klf-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/606—Transcription factors c-Myc
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
    • C12N2506/1361—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from dental pulp or dental follicle stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

The purpose of the present invention is to provide immortalized stem cells which produce a growth factor capable of regenerating various kinds of tissues that have been damaged by a variety of causes and a method for producing the aforesaid immortalized stem cells. Another purpose of the present invention is to provide a medicinal composition and a medicinal preparation for restoring damaged tissues and a method for the percutaneous absorption of a culture supernatant. Provided are immortalized stem cells that are obtained by isolating stem cells selected from the group consisting of mammalian mesenchymal cells an embryo at the early stage of the development and somatic cells first culturing the cells to give first stage culture cells transferring four kinds of genes into the first stage culture cells to give transgenic cells and selecting the desired immortalized stem cells from among the transgenic cells using the expression of STRO 1 as an index. Also provided are a medicinal composition and a medicinal preparation for restoring damaged tissues which comprise a culture supernatant of the immortalized stem cells as the active ingredient.
IN8862DEN2014 2012-03-28 2013-03-28 IN2014DN08862A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2012073594 2012-03-28
JP2012187321 2012-08-28
JP2012275169 2012-12-17
JP2013026886 2013-02-14
PCT/JP2013/059376 WO2013147082A1 (en) 2012-03-28 2013-03-28 Immortalized stem cells and medicinal composition and medicinal preparation comprising product thereof as active ingredient

Publications (1)

Publication Number Publication Date
IN2014DN08862A true IN2014DN08862A (en) 2015-05-22

Family

ID=49260325

Family Applications (1)

Application Number Title Priority Date Filing Date
IN8862DEN2014 IN2014DN08862A (en) 2012-03-28 2013-03-28

Country Status (10)

Country Link
US (2) US20150203821A1 (en)
EP (1) EP2832851B1 (en)
JP (1) JP6010112B2 (en)
KR (2) KR101930718B1 (en)
CN (2) CN110079503A (en)
CA (1) CA2868251C (en)
IN (1) IN2014DN08862A (en)
RU (1) RU2619221C2 (en)
SG (1) SG11201406141UA (en)
WO (1) WO2013147082A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104981547A (en) * 2012-12-26 2015-10-14 石匠株式会社 Highly functional implant material
CN106102754B (en) * 2014-01-24 2020-04-17 石匠株式会社 Pharmaceutical composition for cancer treatment and pharmaceutical preparation for cancer treatment containing the same as active ingredient
EP3101121B1 (en) * 2014-01-27 2019-12-11 Beijing Stomatology Hospital, Capital Medical University Use of genetically modified odontogenic stem cells
JP2016150919A (en) * 2015-02-18 2016-08-22 ピアス株式会社 Cosmetic composition for application
JP2016210730A (en) * 2015-05-08 2016-12-15 上田　実 Pharmaceutical compositions and production methods thereof as well as pharmaceuticals
CN105251053B (en) * 2015-09-23 2018-09-04 广州赛莱拉干细胞科技股份有限公司 Cell complex for periodontal tissue repair and application thereof
WO2017078176A1 (en) * 2015-11-05 2017-05-11 株式会社Ｑｕａｒｒｙｍｅｎ＆Ｃｏ． Immortalized stem cells, and method for producing same
JP6830768B2 (en) * 2016-06-16 2021-02-17 株式会社Ｃｙｓａｙ Wound covering agent and wound covering sheet
JP6152205B1 (en) * 2016-08-09 2017-06-21 仁幸 小林 Cosmetics, pharmaceutical compositions, and methods for producing them
CN106267165A (en) * 2016-08-29 2017-01-04 楼秀余 HGH and IGF 1 liposome complex capsule and preparation method thereof
TWI649422B (en) * 2016-12-30 2019-02-01 中國醫藥大學 Adult multifunctional olfactory stem cells, separation method and application thereof
FR3068366B1 (en) * 2017-06-30 2023-11-24 Francais Du Sang Ets METHOD FOR PRODUCING ERYTHROID PROGENITORS
WO2019027299A2 (en) * 2017-08-04 2019-02-07 주식회사 에스엘바이젠 Pharmaceutical composition for preventing or treating vascular disorders including mesenchymal stem cell expressing hepatocyte growth factor as active ingredient
WO2019027298A2 (en) * 2017-08-04 2019-02-07 주식회사 에스엘바이젠 Pharmaceutical composition comprising mesenchymal stem cell expressing trail and cd as effective ingredient for prevention or treatment of cancer
RU2679082C1 (en) * 2017-12-13 2019-02-05 Общество с ограниченной ответственностью "Покровский банк стволовых клеток" Method for extracting a tooth pulp for receiving culture of stem cells
CN108070567A (en) * 2018-01-19 2018-05-25 皓昇莱生物制药有限公司 A kind of urine derived cell strain of immortalization and its construction method
JP6923137B2 (en) * 2018-06-15 2021-08-18 有限会社大阪空気機械サービス Tissue healing agent
KR20200129266A (en) * 2019-05-08 2020-11-18 경상대학교산학협력단 Pharmaceutical composition for preventing or treating male infertility comprising dental tissue-derived mesenchymal stem cells
CN110951683A (en) * 2020-01-06 2020-04-03 深圳华云生物科技发展有限公司 Preparation method of dental pulp stem cells
KR102572595B1 (en) * 2020-12-02 2023-08-31 충북대학교 산학협력단 Composition for preventing or treating anti-inflammatory diseases comprising immortalized feline mesenchymal stem cells and their exosome-rich conditoned medium
KR102456805B1 (en) * 2020-12-02 2022-10-24 충북대학교 산학협력단 Composition for preventing or treating anti-inflammatory diseases comprising immortalized canine mesenchymal stem cells and their exosome-rich conditioned medium
JPWO2022244851A1 (en) * 2021-05-19 2022-11-24

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554512A (en) * 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
US20030049236A1 (en) * 2001-07-27 2003-03-13 Arhus Amt Immortalized stem cells
JP3897717B2 (en) * 2002-04-23 2007-03-28 オリンパス株式会社 Cell transplantation treatment material and method for producing the same
JP4831687B2 (en) 2004-07-23 2011-12-07 株式会社カネカ Method for inducing differentiation from mesenchymal stem cells to odontoblasts
US8372797B2 (en) * 2006-06-22 2013-02-12 Creative Medical Health, Inc. Treatment of erectile dysfunction by stem cell therapy
CN101063150B (en) * 2007-04-24 2010-05-26 浙江大学 Method for transduction of bone marrow mesenchyma stem cell by human telomerase gene
JP2008307007A (en) * 2007-06-15 2008-12-25 Bayer Schering Pharma Ag Human pluripotent stem cell induced from human tissue-originated undifferentiated stem cell after birth
KR101564044B1 (en) * 2007-10-31 2015-10-28 고쿠리츠 다이가쿠 호진 교토 다이가쿠 Nuclear Reprogramming Method
US20110151447A1 (en) * 2007-11-06 2011-06-23 Children's Medical Center Corporation Method to produce induced pluripotent stem (ips) cells from non-embryonic human cells
JP5562231B2 (en) * 2008-07-30 2014-07-30 国立大学法人京都大学 Efficient method for establishing induced pluripotent stem cells
JP2010046019A (en) * 2008-08-21 2010-03-04 Toyama Univ Human amnion-derived mesenchymal cell and diabetic medicine using the same
SG193887A1 (en) * 2008-09-22 2013-10-30 Agency Science Tech & Res Method of improving differentiation of chondrogenic progenitor cells
WO2010105257A2 (en) * 2009-03-13 2010-09-16 The Salk Institute For Biological Studies Generation of mouse induced pluripotent stem cells bytransient expression of a single non- viral polycistronic vector
KR101764437B1 (en) * 2009-03-20 2017-08-02 메소블라스트, 아이엔씨. Production of reprogrammed pluripotent cells
US20130195991A1 (en) * 2010-03-26 2013-08-01 National University Corporation Nagoya University Composition for Treatment of Damaged Part
JP6132459B2 (en) * 2011-07-13 2017-05-24 株式会社 バイオミメティクスシンパシーズ Prophylactic / therapeutic agent for enteritis containing culture supernatant of mesenchymal stem cells

Also Published As

Publication number Publication date
RU2014143266A (en) 2016-05-20
CA2868251C (en) 2019-02-12
CN104321426A (en) 2015-01-28
SG11201406141UA (en) 2014-10-30
US20170355960A1 (en) 2017-12-14
US20150203821A1 (en) 2015-07-23
US10494606B2 (en) 2019-12-03
KR20170121340A (en) 2017-11-01
KR101930718B1 (en) 2018-12-19
EP2832851B1 (en) 2019-04-17
CA2868251A1 (en) 2013-10-03
EP2832851A4 (en) 2015-09-02
CN110079503A (en) 2019-08-02
EP2832851A1 (en) 2015-02-04
JPWO2013147082A1 (en) 2015-12-14
WO2013147082A1 (en) 2013-10-03
JP6010112B2 (en) 2016-10-19
KR20150009528A (en) 2015-01-26
RU2619221C2 (en) 2017-05-12

Similar Documents

Publication Publication Date Title
IN2014DN08862A (en)
BR112017007770A2 (en) in vitro culture, hipscs population, method for modifying a genomic target locus, and, hipsc.
PH12014501175A1 (en) Medium composition for rejuvenating stem cells
MY156588A (en) Systems using cell culture for production of isoprene
BR112015019950A2 (en) METHOD TO GENERATE MOUSE EMBRYONIC STEM CELL (ES) LINEAGE AND IN VITRO CULTURE
SG178914A1 (en) Stem cell conditioned medium compositions
EP3612623A4 (en) Compositions and methods for increasing the culture density of a cellular biomass within a cultivation infrastructure
WO2011149762A3 (en) Method of nociceptor differentiation of human embryonic stem cells and uses thereof
WO2010141801A3 (en) Reprogramming t cells and hematophietic cells
MX2012010597A (en) Enterobacter sp. 638 and methods of use thereof.
WO2010096588A3 (en) Cell culture media containing combinations of proteins
MY162649A (en) Plant stem cell line derived from cambium of herbaceous plant with stroge root and method for isolating the same
BRPI0813729B8 (en) methods of preparing cell masses of purified cardiomyocytes derived from pluripotent stem cells and a film of cardiomyocyte cell masses, as well as medical device and use of said cell masses
UA117448C2 (en) Compositions and methods for enhancing bioenergetic status in female germ cells
MY151979A (en) Method for producing mesenchymal stem cells from human pluripotent stem cells, and mesenchymal stem cells produced by same
NZ609731A (en) Compositions of adult organ stem cells and uses thereof
MX2019008002A (en) Microbial compositions and methods.
WO2011091350A3 (en) Methods & compositions for improving protein production
WO2017075276A3 (en) Compositions and methods for chimeric embryo-assisted organ production
EP3940062A4 (en) Cosmetic composition comprising culture solution of mesenchymal stem cells cultured in hpl-containing medium
WO2012131733A3 (en) Media compositions for enriching cultures of stem cells
WO2012141471A3 (en) Method for preparing induced pluripotent stem cells using a dedifferentiation enhancer
WO2017049240A8 (en) Selection of pluripotent cells for production of fertile xy female mice
WO2012071393A3 (en) Method for producing pluripotent stem cells
MY173319A (en) A method and a system for mass-cultivating microalgae with enhanced photosynthetic efficiency